Abstract:PURPOSE:The difference between combinational and pre-planned sequential therapies using regimens that include non-anthracycline and taxane in the first-line setting remains unclear. The purpose of this study is to explore the interaction between vinorelbine (N) and capecitabine (X) in breast cancer cells and to compare the simultaneous or sequential administration of the two drugs in patients with metastatic breast cancer (MBC) as first-line treatment.METHODS:First, we explored the effects of vinorelbine on thymidine phosphorylase (TP) and thymidylate synthase (TS) expression in breast cancer cells. Next, we designed a prospective randomized phase II trial of MBC patients comparing the combinational and pre-planned sequential administration of vinorelbine and capecitabine in the first-line metastatic setting. The primary end point was progression-free survival (PFS). The correlation between clinical characteristics and class III β-tubulin expression and patient survival was also explored.RESULTS:Vinorelbine upregulates TP and downregulates TS in breast cancer cells, thereby further sensitizing tumor cells to capecitabine, which indicated the proper order for sequential therapy should be N → X. Sixty patients were eligible for the phase II trial. No significant difference was observed between the combinational arm and the sequential arm in terms of progression-free survival (PFS), overall response rate (ORR), and overall survival (OS). Only in the subgroup of patients with liver metastases were median PFS and OS significantly prolonged in the combinational arm (8.5 vs. 6.4 months, P = 0.041 and 23.8 vs. 13.9 months, P = 0.028, respectively). No association between class III β-tubulin expression and patient outcome was identified. Grade 3/4 adverse events were more common in the combinational arm.CONCLUSIONS:Both the NX regimen and pre-planned sequential N → X regimen are acceptable as first-line treatments with comparable efficacies for MBC patients previously treated with anthracyclines and/or taxanes. Sequential monotherapies are recommended as the preferred approach to first-line chemotherapy for most MBC patients in the absence of an imminent visceral crisis and the need for rapid symptom and/or disease control.

Vinorelbine and the topoisomerase 1 inhibitors: Current and potential roles in breast cancer chemotherapy

A Systematic Review of Vinorelbine for the Treatment of Breast Cancer.

Vinorelbine tartrate (Navelbine): drug profile and nursing implications of a new vinca alkaloid

Topoisomerase Inhibitors in Metastatic Breast Cancer: Overview of Current Practice and Future Development

Vinorelbine based combination chemotherapy in advanced non-small cell lung cancer

Clinical and molecular characterization of the vinorelbine-platinum chemotherapeutic regimen in HER2(-) metastatic breast cancer

The Clinical Study of Post-operation Treatment in Patients with Stage-Ⅱ, Ⅲa Breast Cancer

Evaluation of Efficacy and Toxicity of Gemcitabine in Combination with Vinorelbine in Metastatic Breast Cancer Patients Previously Treated with Anthracyclines and Taxanes

Anti-tubulin agent vinorelbine inhibits metastasis of cancer cells by regulating epithelial-mesenchymal transition

Distinct Characterization of Two Vinorelbine-Resistant Breast Cancer Cell Lines Developed by Different Strategies.

Oral vinorelbine in combination with cisplatin: a novel active regimen in advanced non-small-cell lung cancer

[Efficacy and Toxicity of Vinorelbine (Nvb)-Based Regimens in Patients with Metastatic Triple Negative Breast Cancer (mtnbc) Pretreated with Anthracyclines and Taxanes].

Topoisomerase I Inhibitors in the Combined Modality Therapy of Lung Cancer

Overcoming Breast Cancer Drug Resistance: A Novel Approach Using siRNA-Mediated P-glycoprotein Downregulation to Enhance Vinorelbine Efficacy

Recent developments in the clinical activity of topoisomerase-1 inhibitors

A Prospective Phase Ii Trial Of Vinorelbine Plus Oxaliplatin In Second- Or Third-Line Metastatic Triple-Negative Breast Cancer

[Effects and Toxicity of Neoadjuvant Chemotherapy with Vinorelbine and Cisplatin in Treatment of Operable Breast Cancer Previously Non-Responsive to Anthracyclines and Taxanes-Containing Regimen: Analysis of 19 Cases].

Vinorelbine Alters lncRNA Expression in Association with EGFR Mutational Status and Potentiates Tumor Progression Depending on NSCLC Cell Lines’ Genetic Profile

A Clinical Study on the Safety of Vinorelbine Combined with Cisplatin in the Treatment of the Postoperative Adjuvant Chemotherapy in Breast Cancer

[Effects of vinorelbine plus cisplatin as second-line neoadjuvant chemotherapy regimen in the treatment of breast cancer].

Vinorelbine and Capecitabine in Anthracycline- And/or Taxane-Pretreated Metastatic Breast Cancer: Sequential or Combinational?